Wall Street brokerages expect Agios Pharmaceuticals Inc (NASDAQ:AGIO) to post $13.42 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Agios Pharmaceuticals’ earnings. The highest sales estimate is $17.00 million and the lowest is $10.60 million. Agios Pharmaceuticals posted sales of $10.51 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 27.7%. The business is expected to announce its next quarterly earnings results on Thursday, May 3rd.
On average, analysts expect that Agios Pharmaceuticals will report full-year sales of $13.42 million for the current year, with estimates ranging from $58.30 million to $215.80 million. For the next financial year, analysts expect that the company will post sales of $274.92 million per share, with estimates ranging from $85.66 million to $734.10 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.65) by ($0.16). The company had revenue of $9.80 million for the quarter, compared to analysts’ expectations of $12.65 million. Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. The business’s revenue was down 56.7% compared to the same quarter last year. During the same period last year, the business posted ($1.34) earnings per share.
A number of equities analysts have recently commented on the stock. BidaskClub raised shares of Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 3rd. SunTrust Banks reaffirmed a “buy” rating and set a $101.00 target price (up from $80.00) on shares of Agios Pharmaceuticals in a research report on Thursday, February 15th. JPMorgan Chase & Co. raised their target price on shares of Agios Pharmaceuticals from $76.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Credit Suisse Group lifted their price objective on shares of Agios Pharmaceuticals from $66.00 to $80.00 and gave the company an “outperform” rating in a report on Thursday, February 15th. They noted that the move was a valuation call. Finally, Needham & Company LLC lifted their price objective on shares of Agios Pharmaceuticals from $72.00 to $86.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Four research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $85.50.
In related news, insider Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $65.00, for a total transaction of $195,000.00. Following the transaction, the insider now directly owns 56,059 shares of the company’s stock, valued at $3,643,835. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO David P. Schenkein sold 53,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $73.16, for a total transaction of $3,877,480.00. Following the transaction, the chief executive officer now directly owns 53,000 shares in the company, valued at $3,877,480. The disclosure for this sale can be found here. Over the last three months, insiders have sold 191,180 shares of company stock worth $14,758,309. 5.43% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGIO. Ark Investment Management LLC grew its holdings in Agios Pharmaceuticals by 66.2% in the second quarter. Ark Investment Management LLC now owns 10,713 shares of the biopharmaceutical company’s stock worth $551,000 after purchasing an additional 4,267 shares during the last quarter. Royal Bank of Canada grew its holdings in Agios Pharmaceuticals by 40.8% in the second quarter. Royal Bank of Canada now owns 9,131 shares of the biopharmaceutical company’s stock worth $470,000 after purchasing an additional 2,648 shares during the last quarter. Nationwide Fund Advisors grew its holdings in Agios Pharmaceuticals by 37.8% in the third quarter. Nationwide Fund Advisors now owns 6,344 shares of the biopharmaceutical company’s stock worth $423,000 after purchasing an additional 1,740 shares during the last quarter. Pictet Asset Management Ltd. grew its holdings in Agios Pharmaceuticals by 198.9% in the third quarter. Pictet Asset Management Ltd. now owns 54,700 shares of the biopharmaceutical company’s stock worth $3,651,000 after purchasing an additional 36,400 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System grew its holdings in Agios Pharmaceuticals by 6.9% in the third quarter. State Board of Administration of Florida Retirement System now owns 54,139 shares of the biopharmaceutical company’s stock worth $3,614,000 after purchasing an additional 3,510 shares during the last quarter. 82.40% of the stock is currently owned by institutional investors and hedge funds.
Shares of Agios Pharmaceuticals (NASDAQ AGIO) traded down $0.61 during trading hours on Friday, hitting $82.94. 726,028 shares of the stock were exchanged, compared to its average volume of 656,018. The stock has a market capitalization of $4,777.04, a price-to-earnings ratio of -12.31 and a beta of 2.02. Agios Pharmaceuticals has a fifty-two week low of $45.11 and a fifty-two week high of $85.88.
TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Anticipate Agios Pharmaceuticals Inc (AGIO) Will Announce Quarterly Sales of $13.42 Million” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://ledgergazette.com/2018/03/17/zacks-analysts-anticipate-agios-pharmaceuticals-inc-agio-will-announce-quarterly-sales-of-13-42-million.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.